Search Results

Heparin-Calibrated Anti-Factor Xa Assay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and Edoxaban.

• Authors : Hyo-Suk Ahn; Hyojin Chae; Yeongsic Kim

Subjects: APIXABAN; EDOXABAN; ORAL medicationAXA SA

• Source: Clinical Laboratory; 2024, Vol. 70 Issue 9, p1682-1689, 8p

Record details

Anti–factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation.

• Authors : Vo, Tai; Bello, Abdel; Ragan, Monika

Subjects: PARTIAL thromboplastin time; RESEARCH; THROMBOSIS

• Source: American Journal of Health-System Pharmacy. 2023 Supplement, Vol. 80, pS77-S83. 7p. 2 Charts, 1 Graph.

Record details

Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury.

• Authors : Aprilliano, Bianca; Giuliano, Christopher; Paxton, Renee Alexander

Subjects: APIXABAN; HEPARIN; ACUTE kidney failureDETROIT (Mich.)

• Source: Pharmacotherapy; Feb2023, Vol. 43 Issue 2, p129-135, 7p

Record details

Anti‐factor Xa as the preferred assay to monitor heparin for the treatment of pulmonary embolism.

• Authors : Zhu, Eric; Yuriditsky, Eugene; Raco, Veronica

Subjects: HEMORRHAGE risk factors; THROMBOEMBOLISM prevention; HEMORRHAGE preventionNEW York (State)

• Source: International Journal of Laboratory Hematology; Apr2024, Vol. 46 Issue 2, p354-361, 8p

Record details

Evaluation of Heparin Anti--Factor Xa Levels Following Antithrombin Supplementation in Pediatric Patients Supported With Extracorporeal Membrane Oxygenation.

• Authors : Gordon, Sharon E.; Heath, Travis S.; McMichael, Ali B. V.

Subjects: EXTRACORPOREAL membrane oxygenation; ANTITHROMBINS; DRUG monitoring

• Source: Journal of Pediatric Pharmacology & Therapeutics; 2020, Vol. 25 Issue 8, p717-722, 6p

Record details

Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions.

• Authors : Faust, Andrew C.; Kanyer, Dave; Wittkowsky, Ann K.

Subjects: BLOOD coagulation factors; CHROMATOGRAPHIC analysis; DRUG monitoring

• Source: American Journal of Health-System Pharmacy. 12/15/2016, Vol. 73 Issue 24, p2037-2041. 5p. 1 Chart.

Record details

"Unit Dose Formulation Of Antidotes For Factor Xa Inhibitors And Methods Of Using The Same" in Patent Application Approval Process (USPTO 20240189401).

Subjects: PATENT applications; ANTIDOTES; HEPARIN

• Source: Drug Week; 7/5/2024, p700-700, 1p

Record details

Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children.

• Authors : Haftmann, Richard J.; Pineda, Erika May; Hall, Brent A.

Subjects: PARTIAL thromboplastin time; CHILD patients; EXTRACORPOREAL membrane oxygenation

• Source: Journal of Pediatric Pharmacology & Therapeutics; 2023, Vol. 28 Issue 3, p228-234, 7p

Record details

A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti–Factor Xa Concentrations.

• Authors : Levito, Marissa N.; Coons, James C.; Verrico, Margaret M.

Subjects: BLOOD coagulation factors; HEPARIN; ORAL medication

• Source: Annals of Pharmacotherapy; May2021, Vol. 55 Issue 5, p618-623, 6p

Record details

Studies from University of Oklahoma Yield New Information about Factor Xa (Antithrombin Supplementation Attenuates Heparin Resistance In Plasma Spiked With Gla-domainless Factor Xa S195a In Vitro).

Subjects: HEPARIN; BLOOD coagulation factors; PROTEOLYTIC enzymesOKLAHOMA City (Okla.)

• Source: Medical Devices & Surgical Technology Week; 7/7/2024, p553-553, 1p

Record details